Aspire Biopharma Holdings (ASBP) Other Operating Expenses (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Other Operating Expenses of $296723.0 for Q1 2026, up 34.97% year-over-year from $219839.0 in Q1 2025, and up 196.62% quarter-over-quarter from $100035.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Other Operating Expenses (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other Operating Expenses for 3 consecutive years, with $296723.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 34.97% year-over-year to $296723.0; the TTM figure through Mar 2026 stood at $779442.0 (up 310.0% YoY), while the FY2025 annual figure was $923914.0, up 540.02% from the prior year.
- Other Operating Expenses rose to $296723.0 in Q1 2026 per ASBP's latest filing, from $100035.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $425489.0 in Q3 2025 and bottomed at -$86423.0 in Q2 2024.
- Historically, Other Operating Expenses has averaged $108894.2 across 3 years, with a median of $40012.0 in 2024.
- Annual changes were most pronounced in 2025 — Other Operating Expenses soared 2451.2% — and 2026, when it jumped 34.97%.
- Aspire Biopharma Holdings' Other Operating Expenses stood at $40012.0 in 2024, then soared by 150.01% to $100035.0 in 2025, then jumped by 196.62% to $296723.0 in 2026.
- Business Quant data shows ASBP's Other Operating Expenses at $296723.0 in Q1 2026, $100035.0 in Q4 2025, and $425489.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233,482.00 |
| Mar 31, 2026 | 296,723.00 |
| Dec 31, 2025 | 100,035.00 |
| Sep 30, 2025 | 425,489.00 |
| Jun 30, 2025 | -42,805.00 |
| Mar 31, 2025 | 219,839.00 |
| Dec 31, 2024 | 40,012.00 |
| Sep 30, 2024 | 16,678.00 |
| Jun 30, 2024 | -86,423.00 |
| Mar 31, 2024 | 10,500.00 |